Lansoprazolo Teva Italia

Lansoprazole, the active ingredient in Lansoprazolo Teva Italia, is a proton pump inhibitor presented as a tablet for oral use. It suppresses gastric acid secretion and is indicated for the treatment of gastro‑esophageal reflux disease, peptic ulcer disease, erosive esophagitis and Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Lansoprazolo Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Lansoprazole is a proton pump inhibitor used to manage conditions associated with excess gastric acid.

Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by reducing acid exposure. Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. Erosive esophagitis: facilitates mucosal recovery through acid suppression. Helicobacter pylori eradication: enhances antibiotic efficacy when combined in eradication regimens.

Lansoprazole may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation: occasional.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis. - Acute interstitial nephritis: renal impairment. - Hypersensitivity reactions: rash, angioedema, anaphylaxis.

Before initiating therapy, consider the following precautions.

Assess renal function: dose may require adjustment in severe impairment. Evaluate hepatic status: use with caution in moderate to severe liver disease. Long‑term use monitoring: periodic assessment for vitamin B12 deficiency and bone mineral density. Potential for rebound acid hypersecretion: avoid abrupt discontinuation after prolonged therapy. Drug‑specific contraindications: do not use in patients with known hypersensitivity to lansoprazole or other PPIs. Store at room temperature: keep in the original container, protect from moisture and light.

Lansoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy. - High‑dose methotrexate: increased toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: may raise serum concentrations. - Diazepam: potential elevation of plasma levels.